IMMTECH PHARM INC | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (35)

View All

Latest Posts

About This Stock More About This Stock
Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO; Climbs 56% On First Day
Article By: ChinaBio® Today
Saturday, December 12, 2020 1:09 PM EDT
JD Health of Guangzhou, the online health-care arm of China e-commerce giant JD.com, completed a $3.5 billion Hong Kong IPO and rose 56% in its first trading session. The company now has a $45 billion market capitalization.
In this article: PFE, IMMP, TCEHY, SVA, BABA, JD
Read
The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO
Article By: Benzinga
Thursday, September 17, 2020 10:48 AM EDT
Here's a roundup of top developments in the biotech space over the last 24 hours.
In this article: BMY, LLY, NVS, PFE, IMMP, AMGN, CLVS, TSLA, VRTX, MRNA, SBBP, VBIV, BNTX, CRDF, GTH, NCNA, KZR
Read
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Article By: Benzinga
Sunday, September 13, 2020 2:40 PM EDT
Biotech stocks continued to remain under pressure in the week ended September 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of news flow on the coronavirus vaccine front.
In this article: AZN, IMMP, ALKS, CLVS, AGEN, PRTA, VSTM, MRSN, BHC, ETON
Read
Protalix BioTherapeutics Announces FDA Acceptance Of BLA For The Treatment Of Fabry Disease And Grants Priority Review
Article By: TalkMarkets Newswire
Tuesday, August 11, 2020 9:05 AM EDT
Priority Review is granted to therapies that the FDA determines have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions.
In this article: PLX Also: IMMP, SRNE, TTOO, OPGN, OXBR
Read
VistaGen Therapeutics Announces Positive Meeting With FDA Regarding Pivotal Phase 3 Study Of PH94B For Acute Treatment Of Anxiety In Patients With Social Anxiety Disorder
Article By: TalkMarkets Newswire
Thursday, July 23, 2020 9:00 AM EDT
VistaGen and the FDA reached consensus on key aspects of a unique initial pivotal Phase 3 clinical trial of PH94B involving a single-event, laboratory-simulated public speaking challenge in adult patients with SAD.
In this article: VTGN Also: IMMP, ARTX, SAGE, RLMD, BHVN
Read
All Posts

Latest Tweets for $IMMP

No tweets yet!

PARTNER HEADLINES